[bAla8]-Neurokinin A(4-10)NK2 agonist CAS# 122063-01-8 |
- Omeprazole
Catalog No.:BCC1254
CAS No.:73590-58-6
- Concanamycin A
Catalog No.:BCC3919
CAS No.:80890-47-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 122063-01-8 | SDF | Download SDF |
PubChem ID | 123943 | Appearance | Powder |
Formula | C35H56N8O10S | M.Wt | 780.93 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | MEN 10210 | ||
Solubility | Soluble to 1 mg/ml in 5% NH4OH / water | ||
Sequence | DSFVALM (Modifications: Ala-5 = β-Ala, Met-7 = C-terminal amide) | ||
Chemical Name | (3S)-3-amino-4-[[(2S)-1-[[1-[[(2S)-1-[[3-[[1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-oxopropyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid | ||
SMILES | CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CCNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CO)NC(=O)C(CC(=O)O)N | ||
Standard InChIKey | CKNPSJOMUQBPLA-FMGAJUQSSA-N | ||
Standard InChI | InChI=1S/C35H56N8O10S/c1-19(2)15-24(32(50)40-23(30(37)48)12-14-54-5)39-27(45)11-13-38-35(53)29(20(3)4)43-33(51)25(16-21-9-7-6-8-10-21)41-34(52)26(18-44)42-31(49)22(36)17-28(46)47/h6-10,19-20,22-26,29,44H,11-18,36H2,1-5H3,(H2,37,48)(H,38,53)(H,39,45)(H,40,50)(H,41,52)(H,42,49)(H,43,51)(H,46,47)/t22-,23-,24?,25?,26-,29-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | NK2 receptor agonist (pD2 = 6.91). Produces bladder contraction and bronchospasm in guinea pigs in vivo. |
[bAla8]-Neurokinin A(4-10) Dilution Calculator
[bAla8]-Neurokinin A(4-10) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Khayalenoid E
Catalog No.:BCN6111
CAS No.:1220508-29-1
- Monomethyl lithospermate B
Catalog No.:BCN2533
CAS No.:122021-74-3
- PLP (139-151)
Catalog No.:BCC5920
CAS No.:122018-58-0
- Cyhalofop
Catalog No.:BCC5474
CAS No.:122008-78-0
- Niazirin
Catalog No.:BCN7300
CAS No.:122001-32-5
- Sulfamonomethoxine
Catalog No.:BCC9156
CAS No.:1220-83-3
- 3-Phenyl-1-propanol
Catalog No.:BCC8102
CAS No.:122-97-4
- Phenylacetaldehyde
Catalog No.:BCN3819
CAS No.:122-78-1
- Cinnamyl cinnamate
Catalog No.:BCN4722
CAS No.:122-69-0
- (-)-Ampelopsin H
Catalog No.:BCC8842
CAS No.:
- Zingerone
Catalog No.:BCN1192
CAS No.:122-48-5
- Glycerine trioleate
Catalog No.:BCN2287
CAS No.:122-32-7
- 2'-O-Acetylsprengerinin C
Catalog No.:BCN6655
CAS No.:1220707-33-4
- Charantadiol A
Catalog No.:BCN3483
CAS No.:1220890-23-2
- 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one
Catalog No.:BCN1602
CAS No.:1220891-22-4
- Auraptenol
Catalog No.:BCN6113
CAS No.:1221-43-8
- 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate
Catalog No.:BCC8575
CAS No.:122111-01-7
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- ER-878898
Catalog No.:BCC8958
CAS No.:122111-11-9
- Acarbose sulfate
Catalog No.:BCC4284
CAS No.:1221158-13-9
- Dehydroborapetoside B
Catalog No.:BCN6601
CAS No.:1221178-16-0
- ML 202
Catalog No.:BCC6306
CAS No.:1221186-52-2
- Meliasenin B
Catalog No.:BCN6112
CAS No.:1221262-77-6
- BP 554 maleate
Catalog No.:BCC6695
CAS No.:1221401-95-1
Tachykinin NK(2) receptors and enhancement of cholinergic transmission in the inflamed rat colon: an in vivo motility study.[Pubmed:11487522]
Br J Pharmacol. 2001 Aug;133(7):1107-13.
In the gastrointestinal tract, tachykinin NK(2) receptors are localized both on smooth muscle and nerve fibres. NK(2) receptor antagonists reduce exaggerated intestinal motility in various diarrhoea models but the site of action contributing to this effect is unknown. In this study we investigated the effects of atropine (1.4 micromol kg(-1), i.v.), hexamethonium (13.5 micromol kg(-1), i.v.), and nepadutant (0.1 micromol kg(-1), i.v.), a selective tachykinin NK(2) receptor antagonist, on distension (0.5 and 1 ml)-, or irritation (acetic acid, 0.5 ml of 7.5% v v(-1))-induced motility in the rat distal colon in vivo. The effects of atropine, hexamethonium or N(omega)-nitro-L-argininemethylester (L-NAME, 1.85 micromol kg(-1), i.v.) on [betaAla(8)]NKA(4-10) (10 nmol kg(-1), i.v.)-induced colonic contractions were also investigated. When the colonic balloon was filled with a subthreshold volume (0.5 ml), the intraluminal instillation of acetic acid triggered a high-amplitude phasic colonic motility which was partially reduced by nepadutant and suppressed by either hexamethonium or atropine. Filling of the balloon with 1 ml evoked reflex (hexamethonium-sensitive), atropine-sensitive phasic colonic motility: nepadutant had no significant effect on the distension-evoked motility. Neither hexamethonium nor atropine significantly reduced [betaAla(8)]NKA(4-10)-induced colonic contractions, whereas nepadutant suppressed them. Following L-NAME pretreatment, [betaAla(8)]NKA(4-10)-induced colonic contractions were inhibited by both atropine and hexamethonium. In hexamethonium-pretreated animals, an atropine-sensitive component of [betaAla(8)]NKA(4-10)-induced colonic contractions was also evident. These results indicate that the application of irritants onto the colonic mucosa induces the release of endogenous tachykinins which enhance excitatory cholinergic mechanisms through the stimulation of NK(2) receptors.
In vivo pharmacology of [beta Ala8]neurokinin A-(4-10), a selective NK-2 tachykinin receptor agonist.[Pubmed:2160369]
Eur J Pharmacol. 1990 Feb 20;177(1-2):81-6.
We studied the effect of [beta Ala8]neurokinin A-(4-10), a newly developed selective NK-2 tachykinin receptor agonist, on various parameters in anaesthetized rats (blood pressure, urinary bladder motility, plasma extravasation) and guinea-pigs (salivation, increase of pulmonary insufflation pressure) as compared to the response produced by tachykinins. [beta Ala8]Neurokinin A-(4-10) was as active as, or more active than, neurokinin A (NKA) or NKA-(4-10) in producing rat bladder contraction or bronchospasm in guinea-pigs, two effects known to involve activation of NK-2 receptors. On the other hand, the synthetic peptide was weakly active, if active at all, in producing hypotension or plasma extravasation in the rat bladder as well as salivation in guinea-pigs, effects known to involve activation of NK-1 receptors. These findings provide evidence that [beta Ala8]NKA-(4-10) acts as a selective NK-2 agonist in vivo and that it can be used to explore the distribution and function of NK-2 receptors.
A potent and selective agonist for NK-2 tachykinin receptor.[Pubmed:2550911]
Peptides. 1989 May-Jun;10(3):593-5.
Replacement of the glycine in position 8 of the C-terminal heptapeptide NKA(4-10) with beta-alanine give rise to a potent and selective agonist for the NK-2 tachykinin receptor. The affinity of [beta-Ala8]-NKA(4-10) to the NK-2 receptor is enhanced by almost one order of magnitude as compared to NKA(4-10), while affinity decreases at about the same extent at NK-1 and NK-3 receptors, respectively. Synthesis and biological activities of a series of NKA(4-10) analogues systematically replaced in each position with beta-alanine are also reported.